Meeting
2017 ASCO Annual Meeting
Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers.
Authors
Jane Bayani
Ontario Institute for Cancer Research, Toronto, ON, Canada
Jane Bayani , Elizabeth Kornaga , Cheryl Crozier , Gun Ho Jang , Irina Kalatskaya , Quang M Trinh , Cindy Q Yao , Julie Livingstone , Annette Hasenburg , Dirk G Kieback , Christos Markopoulos , Luc Dirix , Paul Christopher Boutros , Melanie Spears , Lincoln D. Stein , Daniel Rea , John Bartlett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 524)
DOI
10.1200/JCO.2017.35.15_suppl.524
Abstract #
524
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.
First Author: Wolfgang Janni
Poster
2016 ASCO Annual Meeting
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
First Author: Oleg Gluz
Poster
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
First Author: Julia M. Greene
Poster
2012 ASCO Annual Meeting
Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.
First Author: Jason Christiansen